Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

July 02, 2013 07:30 ET | Source: Durata Therapeutics, Inc.

Durata Therapeutics to Present at JMP Securities Healthcare Conference

CHICAGO, July 2, 2013 (GLOBE NEWSWIRE) -- Durata Therapeutics (Nasdaq:DRTX) announced today that Paul R. Edick, CEO, will present an overview of the Company at the 8th Annual JMP Securities Healthcare...
May 29, 2013 07:30 ET | Source: Durata Therapeutics, Inc.

Durata Therapeutics to Present at Jefferies 2013 Global Healthcare Conference

CHICAGO, May 29, 2013 (GLOBE NEWSWIRE) -- Durata Therapeutics (Nasdaq:DRTX) announced today that Paul R. Edick, CEO, will present an overview of the Company at the Jefferies 2013 Global Healthcare...
May 16, 2013 13:44 ET | Source: Durata Therapeutics, Inc.

Paul A. Friedman, M.D. is Elected to Durata Therapeutics' Board of Directors

CHICAGO, May 16, 2013 (GLOBE NEWSWIRE) -- Durata Therapeutics (Nasdaq:DRTX) today announced that Paul A. Friedman, M.D. was elected to its Board of Directors at the Company's 2013 Annual Meeting of...
May 09, 2013 07:00 ET | Source: Durata Therapeutics, Inc.

Durata Therapeutics, Inc. Reports First Quarter 2013 Financial Results

-Raised $54 million in Recent Equity Offering- CHICAGO, May 9, 2013 (GLOBE NEWSWIRE) -- Durata Therapeutics, Inc. (Nasdaq:DRTX) today announced financial results for the quarter ended March 31,...
May 07, 2013 07:30 ET | Source: Durata Therapeutics, Inc.

Durata Therapeutics to Present at Bank of America Merrill Lynch 2013 Healthcare Conference

CHICAGO, May 7, 2013 (GLOBE NEWSWIRE) -- Durata Therapeutics (Nasdaq:DRTX) announced today that Paul R. Edick, CEO, will present an overview of the Company at the Bank of America Merrill Lynch...
May 02, 2013 07:30 ET | Source: Durata Therapeutics, Inc.

Durata Therapeutics to Announce First Quarter 2013 Financial Results on May 9, 2013

CHICAGO, May 2, 2013 (GLOBE NEWSWIRE) -- Durata Therapeutics (Nasdaq:DRTX) has scheduled its quarterly conference call for Thursday, May 9 at 8:30 a.m. Eastern Time to discuss first quarter 2013...
April 29, 2013 07:30 ET | Source: Durata Therapeutics, Inc.

New Data Demonstrating In Vitro Potency of Dalbavancin Against Bacterial Pathogens Presented at the 23rd Annual ECCMID Meeting

CHICAGO, April 29, 2013 (GLOBE NEWSWIRE) -- Durata Therapeutics, Inc. (Nasdaq:DRTX) today announced data from surveillance results of its lead product candidate, dalbavancin, under investigation for...
April 29, 2013 07:30 ET | Source: Durata Therapeutics, Inc.

Phase I Data Evaluating Safety, Tolerability and Pharmacokinetics of Multiple Weekly Doses of Dalbavancin Presented at the 23rd Annual ECCMID Meeting

CHICAGO, April 29, 2013 (GLOBE NEWSWIRE) -- Durata Therapeutics, Inc. (Nasdaq:DRTX) today announced data from a Phase 1 study of its lead product candidate, dalbavancin, under investigation for the...
April 24, 2013 07:30 ET | Source: Durata Therapeutics, Inc.

Durata Therapeutics to Present Two Dalbavancin Posters at the 23rd Annual ECCMID Meeting

CHICAGO, April 24, 2013 (GLOBE NEWSWIRE) -- Durata Therapeutics, Inc. (Nasdaq:DRTX) today announced that data from two clinical trials of the company's lead product candidate, dalbavancin, will be...
April 22, 2013 15:30 ET | Source: Durata Therapeutics, Inc.

Durata Therapeutics to Present at the 2013 Needham Healthcare Conference

CHICAGO, April 22, 2013 (GLOBE NEWSWIRE) -- Durata Therapeutics (Nasdaq:DRTX) announced today that Paul R. Edick, CEO, will be presenting at the Needham 12th Annual Healthcare Conference. The formal...